Research programme: cardiovascular therapies - Dybly
Alternative Names: DYB143; DYB186; DYB286Latest Information Update: 16 Jul 2016
At a glance
- Originator Circomed
- Developer Dybly
- Class
- Mechanism of Action Apolipoprotein A-I stimulants; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis; Intermittent claudication; Myocardial infarction
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atherosclerosis in Switzerland (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Intermittent-claudication in Switzerland (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Myocardial-infarction in Switzerland (PO)